Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymox is a botanically-derived antimicrobial technology developed by Laboratoire M2, primarily based on the active ingredient thymol, a constituent of thyme oil. It is widely utilized in veterinary medicine, particularly for the treatment and prevention of digital dermatitis in livestock, and as a broad-spectrum disinfectant in industrial, medical, and domestic settings. The mechanism of action involves the disruption of microbial cell membranes, leading to leakage of cytoplasmic contents and cell death. Unlike many synthetic disinfectants, Thymox is biodegradable and non-toxic, making it a preferred choice for environmentally conscious biosecurity protocols. It is registered as a veterinary drug in several jurisdictions, including Canada, for the control of bovine digital dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Thymox.